13 New Stocks on Deck This Week as Biotechs Lead the Way

How will the Street welcome nine new biotech stocks?

The market for new stocks has been fairly listless during the year. But as for the upcoming week, the activity is going to ramp up. Consider that there are 13 deals on the calendar this week.

biotech-stocks
Source: ©iStock.com/AlexRaths

However, there could be some problems. After all, nine of this week’s deals are biotech operators (including a carryover from last weekCoLucid Pharmaceuticals). Yet the sector has come under lots of pressure.

So for more details on things, let’s take a look at all the deals:

New Stocks to Watch: Gelesis Inc (GLSS)

Expected Offering Date: Wednesday

Gelesis Inc (NASDAQ:GLSS) is a biotech company that is focused on treatments for weight loss and glycemic control. The company relies on a propriety hydrogel technology, which is used exclusively for the gastrointestinal tract — not with surgery.

If the lead drug proves effective, it could help deal with the growing populations of those with obesity and diabetes. But it the treatment still in the early stages. Keep in mind that it will likely not be commercialized until 2019.

Gelesis plans to offer 4 million shares at a price range of $12 to $14. The lead underwriters include Piper Jaffray Companies (NYSE:PJC), Stifel Financial Corp (NYSE:SF) and Guggenheim Securities.

New Stocks to Watch: MultiVir Inc (MVIR)

Expected Offering Date: Wednesday

MultiVir Inc (NASDAQ:MVIR) is a clinical-stage gene therapy company, which is focused on developing oncological treatments. The company has two lead candidates, which include Ad-p53 and Ad-IL24. Ad-p53 delivers a tumor suppressor gene that targets several types of cancers. And as for Ad-IL24, it is another suppressor but delivers the interleukin-24 gene. Both of these have gone through Phase 1 trials.

The company’s management is certainly strong. CEO Robert E. Sobol was a co-founder of Idec Pharmaceuticals Corp., which merged with Biogen Inc (NASDAQ:BIIB).

MultiVir expects to issue 4.6 million shares at a price range of $12 to $14. The lead underwriter is RBC Capital Markets, LLC.

New Stocks to Watch: Adaptimmune Therapeutics PLC (ADAP)

Expected Offering Date: Thursday

Adaptimmune Therapeutics is a biotech company that is developing drugs based on cancer immunotherapy. That is, the technology essentially leverages a patient’s own T-cells. The approach is considered to be safer and more effective than traditional chemical-based drugs.

The lead drug is for the NY-ESO-1, or NY-ESO, which is for synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer. It is currently in clinical trials.

Adaptimmune Therapeutics expects to sell 9.4 million shares at a price range of $15 to $17. The lead underwriters include Bank of America Corp (NYSE:BAC), Cowen & Company and Leerink Partners LLC.

New Stocks to Watch: aTyr Pharma (LIFE)

Expected Offering Date: Thursday

The biotech company aTyr Pharma develops medicines for those who suffer from rare diseases. A key to the company’s approach is Physiocrine biology, which is a cutting-edge area of research in the biotech world. This involves naturally occurring proteins that may promote homeostasis, which is critical for restoring tissue.

The lead candidate is Resolaris, which has completed Phase I trials. The drug is for the treatments of facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy.

The company plans to issue 5.4 million shares at a price range of $13 to $15. The lead underwriters include JPMorgan Chase & Co. (NYSE:JPM) and Citigroup Inc (NYSE:C).

New Stocks to Watch: Collegium Pharmaceutical, Inc. (COLL)

Expected Offering Date: Thursday

Collegium Pharmaceutical, Inc. is a biotech company that is focused on creating abuse-deterrent drugs for pain, which are based on a patented system called DETERx. The lead product is Xtampza, an oral formulation of oxycodone (a prescription opioid). In fact, the drug has received fast-track status with the FDA and review is expected to be completed on Oct. 12.

The market potential is large. A similar drug — Oxycontin — generated $2.5 billion in sales last year in the U.S.

Collegium Pharmaceutical expects to issue 5.8 million shares at a price range of $12 to $14. The lead underwriters include Jefferies Group LLC and Piper Jaffray.

New Stocks to Watch: Commercial Credit Inc (CCR)

Expected Offering Date: Thursday

Commercial Credit Inc (NYSE:CCR) is a financial services company that is focused on the commercial equipment market. The financing includes mostly loans — but there are also some leases. Targets market segments include construction, fleet transportation and waste industries in the U.S. and Canada.

For the first nine months of 2014, net income came to $9 million, up from $6.6 million in the same period a year earlier. The total receivables in the portfolio are roughly $604.3 million.

Commercial Credit expects to issue 7.3 million shares at a price range of $15 to $17. The lead underwriters include JPM and Keefe Bruyette Woods.

New Stocks to Watch: HTG Molecular Diagnostics (HTGM)

Expected Offering Date: Thursday

HTG Molecular Diagnostics is a biotech company that operates a platform that allows for complex molecular profiling. The systems included instruments, consumables and even software analytics.

With the growth in areas like immune-oncology, there has also been an increased demand for profiling. It also helps that HTG’s solution allows for small samples and quick turnarounds.

The company estimates the current market opportunity at about $17.8 billion — and it is expected to reach $35 billion by 2018.

HTG Molecular Diagnostics plans to issue 3.6 million shares at a price range of $13 to $15 and the lead underwriter is Leerink Partners.

New Stocks to Watch: Klox Technologies Inc (KLOX)

Expected Offering Date: Thursday

Kloc Technologies Inc (NASDAQ:KLOX) is a specialty pharma company that is developing treatments based on its BioPhotonic technology system. For the most part, it allows for healing skin and soft tissue disorders. The initial indication includes both LumiCleanse and LumiBel, which are dermatological systems for acne vulgaris and cosmetic skin care.

Last year, revenues came to $3 million and the net loss was $8.1 million.

Klox Technologies expects to sell 4.8 million shares at a price range of $13 to $15 and the lead underwriter is UBS Group AG (NYSE:UBS)

New Stocks to Watch: Tallgrass Energy GP LP (TEGP)

Expected Offering Date: Thursday

Tallgrass Energy GP LP (NYSE:TEGP) is a master limited partnership with interests in Tallgrass Energy Partners LP (NYSE:TEP). With this structure, investors in TEGP will get more tax-efficient distributions from stable cash-flow generating assets like storage, processing of natural gas, water services and transportation of crude oil.

Once public, the firm is expected to pay a quarterly dividend of 48.5 cents per unit.

TEGP expects to issue 35.3 million shares at a price range of $24 to $27. The lead underwriters include Citigroup, Goldman Sachs Group Inc (NYSE:GS), Bank of America, Barclays PLC (NYSE:BCS), Credit Suisse Group AG (NYSE:CS), Deutsche Bank AG (NYSE:DB), Morgan Stanley (NYSE:MS), RBC Capital Markets and Wells Fargo & Co (NYSE:WFC).

New Stocks to Watch: Anterios (ANTE)

Expected Offering Date: Friday

Anterios Inc (NASDAQ:ANTE) is a clinical-stage biotech company that is focused on developing treatments that use botulinum toxin type A. The current market, which is about $2.8 billion on a global basis, involves drugs that are injected. But as for Anterios, the lead product, ANT-1207, is a topical formulation that will help treat primary axillary hyperhidrosis, or excessive underarm sweating, facial acne, and lateral canthal lines (that is, “crow’s feet”).

Anterios plans to issue 3.9 million shares at a price range of $12 to $14. The lead underwriters include Stifel and RBC Capital Markets.

New Stocks to Watch: International Market Centers (IMC)

Expected Offering Date: Friday

International Market Centers is a real estate investment trust (REIT) that is the largest owner and operator of business-to-business showroom space in North America for home furniture. In all, the portfolio includes 12.1 million gross square feet, with buildings in North Carolina and Las Vegas.

Last year, the company posted revenues of $162.8 million and adjusted EBITDA of $82 million.

International Market Centers plans to issue 11.5 million shares at a price range of $12 to $14. The lead underwriters include Barclays, Credit Suisse, Wells Fargo Securities, Deutsche Bank and J.P. Morgan.

New Stocks to Watch: Bojangles’ Restaurants, Inc. (BOJA)

Expected Offering Date: Friday

Bojangles’ Restuarants, Inc. is a fast-casual restaurant chain with more than 600 locations based primarily in the southern U.S. The menu includes made-from-scratch biscuits, fried chicken and iced tea.

Growth has been robust. During the last 19 consecutive quarters, the company posted increases in comparable restaurant sales.

Bojangles’ plans to sell 6.3 million shares at a price range of $15 to $17. The lead underwriters include Bank of America, Wells Fargo Securities, Jefferies, Barclays, Goldman Sachs, Piper Jaffray, William Blair, KeyBanc Capital Markets and RBC Capital Markets.

Tom Taulli runs the InvestorPlace blog IPO Playbook. He is also the author of High-Profit IPO StrategiesAll About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.

More From InvestorPlace


Article printed from InvestorPlace Media, https://investorplace.com/ipm_ipo_pb/13-new-stocks-on-deck-as-biotechs-lead-the-way-ccr-mvir-glss-ante-tegp-klox/.

©2019 InvestorPlace Media, LLC